Market Place
Sourcing Support
Ipsen Reports Strong H1 2025 Results, Upgrades Full-Year Guidance
31 Jul 2025 //
GLOBENEWSWIRE
Ipsen S.A. Releases 2025 Half-Year Report
31 Jul 2025 //
GLOBENEWSWIRE
IPSEN Initiates Buy-Back Programme - Art 5 of MAR - Week 30, 2025
29 Jul 2025 //
GLOBENEWSWIRE
Cabometyx® Gets EU Approval for Advanced Neuroendocrine Tumors
24 Jul 2025 //
GLOBENEWSWIRE
Ipsen Gets EU OK for CABOMETYX in Neuroendocrine Tumors
24 Jul 2025 //
BUSINESSWIRE
Ipsen Revises Executive Committee
23 Jul 2025 //
CONTRACTPHARMA
Ipsen Reveals Executive Committee Changes
23 Jul 2025 //
GLOBENEWSWIRE
IPSEN Initiates Buy-Back Programme - Art 5 of MAR - Week 29, 2025
22 Jul 2025 //
GLOBENEWSWIRE
IPSEN Initiates Buy-Back Programme - Art 5 of MAR - Week 28, 2025
16 Jul 2025 //
GLOBENEWSWIRE
Ipsen reports voting rights and share capital for June 2025
10 Jul 2025 //
GLOBENEWSWIRE
IRIC and IRICoR Begin Phase 1 Trial for Solid Tumor Therapy
09 Jul 2025 //
PR NEWSWIRE
Ipsen’s Biologics Increlex Receives Suppl Approval in US
09 Jul 2025 //
FDA
IPSEN Initiates Buy-Back Programme - Art 5 of MAR - Week 27, 2025
08 Jul 2025 //
GLOBENEWSWIRE
Ipsen - Half Year Statement - 2025 06 30
07 Jul 2025 //
GLOBENEWSWIRE
IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2025
01 Jul 2025 //
GLOBENEWSWIRE
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2025
24 Jun 2025 //
GLOBENEWSWIRE
Ipsen gets Positive CHMP opinion for Cabometyx in Tumors
20 Jun 2025 //
BUSINESSWIRE
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2025
17 Jun 2025 //
GLOBENEWSWIRE
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2025
13 Jun 2025 //
GLOBENEWSWIRE
Ipsen May 2025 Monthly Voting Rights and Share Capital
12 Jun 2025 //
GLOBENEWSWIRE
Ipsen S.A. - Initiation of Share Buy-Back Program
02 Jun 2025 //
GLOBENEWSWIRE
Onivyde Regimen Linked to Long-Term Survival in Pancreatic Cancer
31 May 2025 //
GLOBENEWSWIRE
Ipsen S.A. - Annual General Meeting held on 21 May 2025
21 May 2025 //
GLOBENEWSWIRE
Genfit to get €26.5M payment for Iqirvo® approval in Italy
20 May 2025 //
GLOBENEWSWIRE
Ipsen - April 2025 - Voting rights and share capital information
12 May 2025 //
GLOBENEWSWIRE
IQIRVO® Data Shows Fatigue Relief, Anti-Inflammatory Impact
07 May 2025 //
GLOBENEWSWIRE
Ipsen Appoints EVP, Strategy & Transformation
06 May 2025 //
CONTRACTPHARMA
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation
06 May 2025 //
PRESS RELEASE
Ipsen S.A. - Preparing for 2025 Annual General Meeting
30 Apr 2025 //
GLOBENEWSWIRE
Ipsen Biopharma`s Iqirvo Receives Approval in Canada
25 Apr 2025 //
HEALTH CANADA
Elafibranor Shows Safety, Efficacy in Rare Liver Disease (PSC) Trial
24 Apr 2025 //
GLOBENEWSWIRE
Ipsen touts early launch results for liver disease drug Iqirvo
17 Apr 2025 //
FIERCE PHARMA
Ipsen reports strong Q1 sales, confirms full-year guidance 2025
16 Apr 2025 //
GLOBENEWSWIRE
Ipsen - March 2025 - Monthly voting rights and shares update
14 Apr 2025 //
GLOBENEWSWIRE
Ipsen publishes its 2024 Universal Registration Document
08 Apr 2025 //
GLOBENEWSWIRE
Ipsen announces issuance of €500 M inaugural Rated Public Bond
19 Mar 2025 //
GLOBENEWSWIRE
Ipsen Appoints Olivia Brown As EVP, Global Head Of Neurotoxins
12 Mar 2025 //
GLOBENEWSWIRE
Ipsen - Feb 2025 - Monthly update on voting rights and shares
06 Mar 2025 //
GLOBENEWSWIRE
Ipsen publishes its 2024 consolidated financial statements
21 Feb 2025 //
GLOBENEWSWIRE
Ipsen Reports Strong 2024 Results & Issues 2025 Guidance
13 Feb 2025 //
GLOBENEWSWIRE
Ipsen Jan 2025 Monthly Info on Voting Rights & Shares
06 Feb 2025 //
GLOBENEWSWIRE
Ipsen - Half year statement - 2024 12 31
07 Jan 2025 //
GLOBENEWSWIRE
Ipsen Shares Monthly Voting Rights And Capital Information
07 Jan 2025 //
GLOBENEWSWIRE
Ipsen - November 2024 Voting Rights & Share Information
09 Dec 2024 //
GLOBENEWSWIRE
Ipsen doubles up in TCEs for cancer, adding Biomunex drug
04 Dec 2024 //
PHARMAPHORUM
Ipsen taps Biomunex`s MAITs to treat solid tumors in $610M bet
03 Dec 2024 //
FIERCE BIOTECH
Ipsen, Biomunex Partner For MAIT Cell Engager In Immuno-Oncology
02 Dec 2024 //
GLOBENEWSWIRE
Bylvay® Data Shows Improvement In Severe Itch & Serum Bile Acids
18 Nov 2024 //
GLOBENEWSWIRE
Iqirvo Data Shows Long Efficacy in PBC with Fatigue Improvement
15 Nov 2024 //
GLOBENEWSWIRE
GENFIT Announces Updates & Participation at Liver Meeting® 2024
13 Nov 2024 //
GLOBENEWSWIRE
Ipsen Monthly Info on Voting Rights & Share Capital (Oct 2024)
07 Nov 2024 //
GLOBENEWSWIRE
Ipsen Delivers Strong Sales Momentum And Raises Guidance
23 Oct 2024 //
GLOBENEWSWIRE
Ipsen receives its second Shingo Prize for operational excellence
14 Oct 2024 //
GLOBENEWSWIRE
UK MHRA Grants Approval For Ipsen’s Elafibranor Treatment
10 Oct 2024 //
PHARMABIZ
Ipsen - September 2024 - Monthly Information On Voting Rights
09 Oct 2024 //
GLOBENEWSWIRE
Ipsen`s IQIRVO Approval Intensifies Primary Biliary Cholangitis
02 Oct 2024 //
PR NEWSWIRE
Ipsen picks up EU approvals for rare disease meds Kayfanda
24 Sep 2024 //
GLOBENEWSWIRE
Ipsen`s Kayfanda Approved In EU For Alagille Syndrome Pruritus
23 Sep 2024 //
GLOBENEWSWIRE
EU Approves Ipsen`s Iqirvo For Biliary Cholangitis
20 Sep 2024 //
GLOBENEWSWIRE
Ipsen Pharma`s Iqirvo (elafibranor) Receives Approval in Europe
19 Sep 2024 //
EMA
